Costs and Benefits in Health Care and Prevention:An International Approach to Priorities in Medicine

Costs and Benefits in Health Care and Prevention:An International Approach to Priorities in Medicine
医学生物化学

原价：

￥ 1799.00

售价：

优惠

平台大促低至8折优惠

发货周期：外国库房发货，通常付款后3-5周到货

作者

U. Laaser; E.J. Rocella; J.B. Rosenfeld; H. Wenzel

出版社

Springer Berlin Heidelberg

出版时间

1990年09月07日

装帧

平装

ＩＳＢＮ

9783540527084

复制

页码

160

开本

9.61 x 6.69 x 0.39

语种

英文

综合评分

暂无评分

图书详情
目次
买家须知
书评（0）
权威书评（0）

图书简介

One of the main purposes of medical cost-benefit analyses is to define the rational priorities in health care. This book ambitiously undertakes to compare the cost-benefit analyses of three countries: the United States, Germany and Israel. Cardiovascular disease is focused on to provide a model case study, but other areas also provide examples. The contribu- tions consider in particular two recent developments. These are the increase in comprehensive epidemiological data, es- pecially with regards to risk factors, and improved methodo- logy for measuring the quality of life. The contributions stem from clinicians, epidemiologists and health economists who give an overall picture of these complex issues and the prospects for the future.

I Introduction.- Epidemiology and Economy, and the Appraisal of Human Life: Ethical and Practical Limitations of how to Value Health Benefits.- II Concepts.- Cost-Effectiveness Analysis, Cost-Benefit Analysis and the Value of Life in Health Care and Prevention.- Cost-Effectiveness Analysis in Health Care: Opportunities and Challenges to International Comparisons.- The Feasibility of Willingness-To-Pay Measurement in Health Services Research.- The Willingness-To-Pay Approach: Caveats to Biased Application.- III Experience.- 1. The Case of a Risk Factor: Hypertension.- Attitude and Behaviour of Stuttgart’s Primary Care Physicians with Regard to the Pharmacological and Non-Pharmacological Treatment of Mild Hypertension.- Comparisons of 1977 and 1987 Physician’s Knowledge Survey — Implications on Cost and Hypertension Management.- Evaluation of Cost-Effectiveness of Physician-Nurse Teams as Compared to Physicians Working alone in Primary Care Practices in Community Control of Hypertension.- The Ashkelon Hypertension Detection and Control Program: Medical and Cost Implications.- The Mangement of Hypertension: A Clinical Dilemma with Health Policy Implications.- 2. The Case of Clinical Disease.- Angina Pectoris Prophylaxis: A Model Estimate of Cost and Benefit.- Cost Considerations for the Management of End Stage Renal Disease in the United States.- Medical Treatment and its Implications on Costs. An Analysis with Process Data from the German Statutory Health Insurance.- IV The New Dimension: Quality of Life.- Quality of Life: Methodological Key Issues.- Towards the Integrated Measurement of Quality of Life.- Quality of Life, Clinical Trials, and Cost-Effectiveness Analysis: Conceptual Issues with Hypertension as an Example.- V Comments on the State of the Art.- Notes on Economic Evaluation.- Some Limitations in the Analysis of Costs and Benefits.- Research Perspectives for the Future: International Cooperation in Comparing Costs and Benefits of the Best Demonstrated Practice in Health Care and Prevention.

Trade Policy 买家须知